All times displayed for Europe/Paris timezone.

Conference | Session 1: Connectivity and Patient-centricity (Connectivité et centricité du patient)

Welcome Coffee & Breakfast
08:30 - 09:00
Opening remarks by the chairs
09:00 - 09:15
Hospital Pharmacist
AP-HP & ANSM Expert
Executive Director
HCPC Europe
Digital Value Added Medicines
09:15 - 09:40
Engagement Manager, European Thought Leadership

• The role of devices in VAMs: Evolution of devices, how companies think of devices now, patient centricity and good product design
• Therapy areas with unmet needs: Which therapy areas lend themselves naturally to disruption from devices
• What does a digital strategy look like? How companies, from innovators to generics can implement an effective digital strategy
• Beyond digital: influencing patient behaviour: What is on the horizon? Gamification as an important element in providing value

Ensuring our digital solutions truly deliver value
09:40 - 10:05
Head, Smart Devices
Roche/ Genentech

• The lessons we have learned to date
- Separating the science from the marketing hype
- Key insights from patients, clinicians, and drug development teams
• What value propositions matter and how should we design products and services to serve them?
- The unique value of device connectivity, approaches to behavioural change and digital partnerships

Break & Refreshments
10:05 - 10:30
Packaging: Labeling setup requirements for, and experiences with, clinical trials and post-market surveillance of pharmaceuticals in relation to patient therapy compliance
10:30 - 10:55
Industrial Project Leader

• Clinical trial packaging design. The key points of concept, differentiation and industrialization.
• Commercial packaging VS Clinical packaging: How to combine the Regulatory Requirements, manufacturing constraints and hospital/patient centricity.
• Solutions for quick and easy identification of clinical boxes.

Enabling smart packaging for pharma through printable and flexible hybrid electronics – how can we make our packaging truly intelligent?
10:55 - 11:20
Strategic Marketing Manager

There are many benefits to the introduction of active and intelligent features to packaging. There is a multitude of technologies available from printed codes through embedded and integrated flexible electronics to complex conventional electronic solutions.
We will give an overview of the different drivers for active and intelligent packaging in pharma and will link these to the appropriate potential technological solutions highlighting the factors needed in the decision making process. We will give examples of where printed or flexible hybrid electronics provide the unique features required for the intended use and will describe what can be achieved with this emerging technology.
We will show why now is the time for smart packaging to shine and how together we can develop an intelligent packaging ecosystem of the future.

Advancing Drug Delivery – Building the Business Case and Creating the Ecosystem for Intelligent Primary Containers
11:20 - 11:45
Managing Director
SHL Group

• Smart objects in prefilled syringes that enable unit-level traceability and industry 4.0 in drug delivery manufacturing
• Open platforms as enablers for new technology throughout the drug-device ecosystem
• Technology partnerships with Pharma and suppliers to implement new technologies
• Intelligent applications to support patient benefits and digital healthcare

Risks and real-world issue with connected devices
11:45 - 12:15
Director of Drug Delivery Device Development

We have heard much about the need for, and advantages of, connected medical devices. In this presentation, we shall cover the main risks and strategies to manage those risks using real-world case studies where possible. The types of risks and strategies that we shall cover include:
• Technical (examples include robustness, complexity, security, data breaches)
• Usability (human factors)
• Supply chain
• Business model
• Regulatory and legal

Lunch break, Exhibition visit
12:15 - 14:00

Conference | Session 2: Substainability (Développement durable)

HPRC(Healthcare Plastics Recycling Council): A Collaborative, Value Chain Approach to Enabling Plastic Recycling
14:00 - 14:20
Technical Marketing Specialist
DuPont™ Tyvek® Healthcare Packaging

The Healthcare Plastics Recycling Council (HPRC) is a private, technical consortium of industry peers across the healthcare, recycling, and waste management industries seeking to improve the recyclability of plastic products and packaging within healthcare. Founded in 2010, and made up of globally recognized members, HPRC engages in pioneering projects designed to help boost plastics recycling efforts in clinical settings of hospitals. Committed to continuous dialogue, HPRC explores ways to enhance the economics, efficiency, and ultimately the quality and quantity of healthcare plastics collected for recycling. In this presentation, you’ll hear about:
• The collaborative approach of HPRC
• Examples of HPRC project work
• Opportunities to get involved with HPRC in Europe

Recovering and managing waste generated by used medicines in the health and medico-social sector
14:20 - 14:40
Purchasing Manager
Starting at the source, sustainable packaging in Merck supply chain
14:40 - 15:15
Associate Director, Head of Sourcing Glass
Merck Healthcare
Global Manager, Product and Packaging Sustainability
Merck Life Sciences

From locating potential issues and monitoring vendors impact, to developing packaging that is easily recyclable, and made using less energy, space or material, this presentation will show how Merck is currently improving packaging sustainability in its supply chain by working in close partnership with its suppliers.

Break & Refreshments
15:15 - 15:30
Implementing circular product design on the journey towards zero environmental impact
15:30 - 15:55
Project Lead, Corporate Environmental Strategy
Novo Nordisk A/S

With the Circular for Zero strategy, Novo Nordisk aims for zero environmental impact by implementing a circular mindset across the organisation. This presentation introduces the Circular for Zero strategy and dives into the Design for circularity track, in which Novo Nordisk has set up a framework for circular design of their products. You will learn how Novo Nordisk has:
• selected indicators to measure progress on circularity
• translated circular economy into a company-specific circular design guideline
• educated employees
• integrated circularity into decision processes in product development

Use of biodegradable materials for disposable drug delivery device design
15:55 - 16:20
Medical Device Innovation Lead
PA Consulting

The single use auto-injectors are disposed of in a sharps bin as medical waste, which is
then incinerated. However, only the syringe is technically considered to be medical waste.
Therefore more of the device than necessary is being discarded as medical waste, wasting
resources and affecting the environment.
PA has developed an eco-friendly concept by :
• Replacing standard materials with biocompatible/ biodegradable materials
• Separating auto-injectors into medical and non-medical waste could make recycling an

Medical blister recycling challenges: first steps into action
16:20 - 16:45
Eco-design services Manager

Blister packs are made primarily of aluminum and PVC, and bring the following end-of-life challenges in France. PVC packaging does not have a recycling stream in France, and mixed plastic/metal packaging is not recyclable in the plastic packaging stream. Moreover, PVC is not welcome as Refuse Derived Fuel. The road to a new recyclable blister to become the standard in the market is long, but will start with cooperation and communication. Only 67% of the public knows how to separate a blister pack for recycling.

Preparing for the Black Swan: A Playbook for Exiting PVC in pharmaceutical flexible packaging
16:45 - 17:10
Managing Director & Co-Founder
Montesino Associates, LLC

According to Investopedia, “A black swan is an extremely rare event with severe consequences. It cannot be predicted beforehand, though many claim it should be predictable after the fact.”
According to Accenture, a playbook includes “process workflows, standard operating procedures, and cultural values that shape a consistent response—the play. A playbook reflects a plan,an approach or strategy defining predetermined responses worked out ahead of time.” In short, a playbook shows maneuvers that form the pieces and parts to getting something done – in this case, exiting PVC. Key strategic factors covered in this playbook: cost, time, regulatory risk.
• Banning PVC: A “Black Swan” event for pharmaceutical flexible packaging
• Machinery Play – maneuvers required for modifying or replacing packaging equipment for non-PVC materials
• Operations Play – maneuvers required at the operational level, including efficiency
• Regulatory Play – maneuvers of what has to be done to establish equivalence
• User Interface Play – maneuvers required to manage the impact of non-PVC structures on the user experience
• Observations for the future…

Panel Discussion
17:10 - 17:45